CA2425363A1 — Benzimidazole compounds, process for producing the same and use thereof
Assigned to Takeda Pharmaceutical Co Ltd · Expires 2003-04-10 · 23y expired
What this patent protects
Compounds represented by the following general formula (I) or salts thereof, which show: (1) excellent antiulcer, gastric acid secretion inhibitory, muco sa- protecting and anti-Helicobacter pyroli effects in vivo; (2) a low toxicity; (3) a high stability to acid (i.e., making …
USPTO Abstract
Compounds represented by the following general formula (I) or salts thereof, which show: (1) excellent antiulcer, gastric acid secretion inhibitory, muco sa- protecting and anti-Helicobacter pyroli effects in vivo; (2) a low toxicity; (3) a high stability to acid (i.e., making it unnecessary to process into enteric preparations, thereby saving the cost and facilitating the intake by patients with dysplagia because of the small size); (4) a higher absorption speed than enteric preparations (i.e., achieving higher expression of the gastric acid secretion inhibitory effect); and (5) a long-lasting effect. In said formula, each symbol is as defined in the description. Thus benzimidazo le compounds, which are highly stable to acid and can be converted into proton pump inhibitors in vivo to thereby exert an antiulcer effect, etc., can be provided.
Drugs covered by this patent
- Dexilant (DEXLANSOPRAZOLE) · Takeda
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.